{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Colorectal+Adenocarcinoma",
    "query": {
      "condition": "Refractory Colorectal Adenocarcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 76,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Colorectal+Adenocarcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:32:18.086Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07147231",
      "title": "Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Adenocarcinoma",
        "Refractory Colorectal Adenocarcinoma",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Unresectable Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pidnarulex",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2026-12-21",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07147231"
    },
    {
      "nct_id": "NCT06910657",
      "title": "IDOV-Immune for Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Renal Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Bladder Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Cervical Cancers",
        "Head and Neck Cancers",
        "Adrenal Gland Tumors"
      ],
      "interventions": [
        {
          "name": "IDOV-Immune (oncolytic vaccinia virus)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ViroMissile, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-08-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910657"
    },
    {
      "nct_id": "NCT00942266",
      "title": "Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Colon",
        "Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2009-07",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-23",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942266"
    },
    {
      "nct_id": "NCT04439292",
      "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-01-04",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439292"
    },
    {
      "nct_id": "NCT05733000",
      "title": "CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Biliary Tract Carcinoma",
        "Advanced Colorectal Carcinoma",
        "Advanced Gastroesophageal Junction Adenocarcinoma",
        "Advanced Lung Adenocarcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Ovarian Carcinoma",
        "Advanced Pancreatic Carcinoma",
        "Advanced Urothelial Carcinoma",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Metastatic Biliary Tract Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Lung Adenocarcinoma",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Pancreatic Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Refractory Biliary Tract Carcinoma",
        "Refractory Colorectal Carcinoma",
        "Refractory Gastroesophageal Junction Adenocarcinoma",
        "Refractory Lung Adenocarcinoma",
        "Refractory Ovarian Carcinoma",
        "Refractory Pancreatic Carcinoma",
        "Refractory Urothelial Carcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Devimistat",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2023-03-08",
      "completion_date": "2030-03-04",
      "has_results": false,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05733000"
    },
    {
      "nct_id": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Solid Tumor",
        "CRAF Gene Amplification",
        "RAF1 Gene Amplification",
        "BRAF Gene Fusion",
        "BRAF Fusion",
        "CRAF Gene Fusion",
        "CRAF Fusion",
        "RAF1 Gene Fusion",
        "RAF1 Fusion",
        "Thyroid Cancer, Papillary",
        "Spitzoid Melanoma",
        "Pilocytic Astrocytoma",
        "Pilocytic Astrocytoma, Adult",
        "Non Small Cell Lung Cancer",
        "Non-Small Cell Adenocarcinoma",
        "Colorectal Cancer",
        "Pancreatic Acinar Carcinoma",
        "Spitzoid Malignant Melanoma",
        "Bladder Cancer",
        "Bladder Urothelial Carcinoma",
        "MAP Kinase Family Gene Mutation",
        "RAF Mutation"
      ],
      "interventions": [
        {
          "name": "Tovorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Day One Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-07-15",
      "completion_date": "2024-07-08",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04985604"
    },
    {
      "nct_id": "NCT07145255",
      "title": "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Castration-resistant Prostate Cancer",
        "Breast Cancer",
        "Colo-rectal Cancer",
        "Lung Cancer (Non-Small Cell)",
        "Pancreas Cancer, Duct Cell Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ADC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MBrace Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-09-03",
      "completion_date": "2029-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07145255"
    },
    {
      "nct_id": "NCT04616183",
      "title": "LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colon Adenocarcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Rectal Adenocarcinoma",
        "Recurrent Colorectal Carcinoma",
        "Stage III Colon Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8",
        "Stage IIIA Colon Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIA Rectal Cancer AJCC v8",
        "Stage IIIB Colon Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIB Rectal Cancer AJCC v8",
        "Stage IIIC Colon Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IIIC Rectal Cancer AJCC v8",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Rectal Cancer AJCC v8",
        "Stage IVA Colon Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVA Rectal Cancer AJCC v8",
        "Stage IVB Colon Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVB Rectal Cancer AJCC v8",
        "Stage IVC Colon Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8",
        "Stage IVC Rectal Cancer AJCC v8",
        "Unresectable Colon Adenocarcinoma",
        "Unresectable Colorectal Carcinoma",
        "Unresectable Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ERK1/2 Inhibitor LY3214996",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2020-12-02",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04616183"
    },
    {
      "nct_id": "NCT00593060",
      "title": "Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey W. Clark, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2007-11-01",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593060"
    },
    {
      "nct_id": "NCT02393755",
      "title": "Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "Rectal Adenocarcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2015-05-08",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-05-21T22:32:18.086Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Buffalo, New York",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393755"
    }
  ]
}